Viquidacin, formerly known as NXL-101, is an orally bioavailable/iv antibiotic targeting Gram positive bacteria such as MRSA. In 2008 Novexel announced that it has discontinued development of viquidacin (NXL 101). The decision was based on QT interval prolongation, which was observed in healthy. References:

纯度：≥98%

CAS：904302-98-3